<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VERAPAMIL HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(ver-ap'a-mill)<br/><span class="topboxtradename">Calan, </span><span class="topboxtradename">Calan SR, </span><span class="topboxtradename">Covera-HS, </span><span class="topboxtradename">Isoptin, </span><span class="topboxtradename">Isoptin SR, </span><span class="topboxtradename">Verelan, </span><span class="topboxtradename">Verelan PM<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">calcium channel blocker</span>; <span class="classification">antiarrhythmic, miscellaneous</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>40 mg, 80 mg, 120 mg tablets; 120 mg, 180 mg, 240 mg sustained-release tablets; 100 mg, 120 mg, 180 mg, 200 mg, 240 mg, 300 mg sustained-release capsules; 5 mg/2 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits calcium ion influx through slow channels into cells of myocardial and arterial smooth muscle. Dilates coronary arteries
         and arterioles and inhibits coronary artery spasm. Decreases and slows SA and AV node conduction without affecting normal
         arterial action potential or intraventricular conduction. Associated vasodilation of arterioles decreases total peripheral
         vascular resistance and reduces arterial BP at rest. May slightly decrease heart rate.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Dilates coronary arteries and inhibits coronary artery spasm, which increases myocardial oxygen delivery and produces an antianginal
         effect. Also decreases nodal conduction, which results in an antiarrhythmic effect.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Supraventricular tachyarrhythmias; Prinzmetal's (variant) angina, chronic stable angina; unstable, crescendo or preinfarctive
         angina and essential hypertension.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Paroxysmal supraventricular tachycardia, atrial fibrillation; prophylaxis of migraine headache; and as alternate therapy in
         manic depression.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe hypotension (systolic 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Duchenne's muscular dystrophy; hepatic and renal impairment; MI followed by coronary occlusion, aortic stenosis.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Angina</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 80 mg q68h, may increase up to 320480 mg/d in divided doses (Note: Covera-HS must be given once daily h.s.)<br/><br/><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 4080 mg t.i.d. or 90240 mg sustained-release 12 times/d up to 480 mg/d (Note: Covera-HS must be given once
               daily h.s.)<br/><br/><span class="indicationtitle">Supraventricular Tachycardia, Atrial Fibrillation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 240480 mg/d in divided doses <span class="rdroute">IV</span> 510 mg IV direct, may repeat in 1530 min if needed<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i>, 0.10.2 mg/kg; <i>115 y</i>, 0.10.3 mg/kg (25 mg)<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food to reduce gastric irritation.</li>
<li>Capsules can be opened and contents sprinkled on food. Do <small>NOT</small> dissolve or chew capsule contents.
         </li>
<li>Give Covera-HS once a day in the evening.</li>
<li>Do not withdraw abruptly; may increase and extend duration of pain in the angina patient.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Direct:</span> Given undiluted or diluted in 5 mL of sterile water for injection. Inspect parenteral drug preparation before administration.
                  Make sure solution is clear and colorless.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose over 23 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Albumin,</b>
<b>aminophylline,</b>
<b>amphotericin B,</b>
<b>hydralazine,</b>
<b>cotrimoxazole.</b>
<span class="incompattype"> Y-site:</span>
<b>Albumin,</b>
<b>amphotericin B cholesteryl complex,</b>
<b>ampicillin,</b>
<b>mezlocillin,</b>
<b>nafcillin,</b>
<b>oxacillin,</b>
<b>propofol,</b>
<b>sodium bicarbonate.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, vertigo, <span class="speceff-common">headache,</span> fatigue, sleep disturbances, depression, syncope. <span class="typehead">CV:</span>
<span class="speceff-common">Hypotension,</span> congestive heart failure, bradycardia, severe tachycardia, peripheral edema, <span class="speceff-life">AV block</span>. <span class="typehead">GI:</span> Nausea, abdominal discomfort, <span class="speceff-common">constipation,</span> elevated liver enzymes. <span class="typehead">Body as a Whole:</span> Flushing, pulmonary edema, muscle fatigue, diaphoresis. <span class="typehead">Skin:</span> Pruritus. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Verapamil may cause elevations of serum <span class="alt">AST,</span>
<span class="alt">ALT,</span>
<span class="alt">alkaline phosphatase.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">beta blockers</span> increase risk of CHF, bradycardia, or heart block; significantly increased levels of <b>digoxin</b> and <b>carbamazepine</b> and toxicity; potentiates hypotensive effects of <span class="classification">hypotensive agents</span>; levels of <b>lithium</b> and <b>cyclosporine</b> may be increased, increasing their toxicity; <b>calcium salts</b> (IV) may antagonize verapamil effects. <span class="typehead">Food:</span>
<b>Grapefruit juice</b> may increase verapamil levels. <span class="typehead">Herbal:</span>
<b>Hawthorne</b> may have additive hypotensive effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 90% absorbed, but only 2530% reaches systemic circulation (first pass metabolism). <span class="typehead">Peak:</span> 12 h PO; 48 h sustained release; 5 min IV. <span class="typehead">Distribution:</span> Widely distributed, including CNS; crosses placenta; present in breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 70% excreted in urine; 16% in feces. <span class="typehead">Half-Life:</span> 28 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness. Drug should decrease angina frequency, nitroglycerin consumption, and episodes of ST segment
            deviation.
         </li>
<li>Establish baseline data and periodically monitor: BP and pulse.</li>
<li>Lab tests: Baseline and periodic liver and kidney functions.</li>
<li>Instruct patient to remain in recumbent position for at least 1 h after dose is given to diminish subjective effects of transient
            asymptomatic hypotension that may accompany infusion.
         </li>
<li>Monitor for AV block or excessive bradycardia when infusion is given concurrently with digitalis.</li>
<li>Monitor I&amp;O ratio during IV and early oral maintenance therapy. Renal impairment prolongs duration of action, increasing potential
            for toxicity and incidence of adverse effects. Advise patient to report gradual weight gain and evidence of edema.
         </li>
<li>Monitor ECG continuously during IV administration. Essential because drug action may be prolonged and incidence of adverse
            reactions is highest during IV administration in older adults, patients with impaired kidney function, and patients of small
            stature.
         </li>
<li>Check BP shortly before administration of next dose to evaluate degree of control during early treatment for hypertension.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Monitor radial pulse before each dose, notify physician of an irregular pulse or one slower than established guideline.</li>
<li>Adhere to established guidelines for exercise program.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Decrease intake of caffeine-containing beverage (i.e., coffee, tea, chocolate).</li>
<li>Change positions slowly from lying down to standing to prevent falls because of drug-related vertigo until tolerance to reduced
            BP is established.
         </li>
<li>Notify physician of easy bruising, petechiae, unexplained bleeding.</li>
<li>Do not use OTC drugs, especially aspirin, unless they are specifically prescribed by physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>